-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Funobactam in Ventilator Associated Pneumonia (VAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Funobactam in Ventilator Associated Pneumonia (VAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Funobactam in Ventilator Associated Pneumonia (VAP) Drug Details: XNW-4107 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Certepetide in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Certepetide in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Certepetide in Gallbladder Cancer Drug Details: Certepetide (CEND-1) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OLX-301A in Geographic Atrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OLX-301A in Geographic Atrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OLX-301A in Geographic Atrophy Drug Details: OLX-301A is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-106 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-106 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2023’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ureter Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Ureter Cancer - Drugs In Development, 2023’, provides an overview of the Ureter Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ureter Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Urethral Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Urethral Cancer - Drugs In Development, 2023’, provides an overview of the Urethral Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urethral Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) - Drugs In Development, 2023’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Gouty Arthritis (Gout) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gouty Arthritis (Gout) - Drugs In Development, 2023’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...